TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03868319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung protective ventilation strategy
Description: low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonprotective ventilation
Description: large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
Study: NCT02613507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT00995358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide
Description: Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
Study: NCT04143607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT06689683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave lithotripsy
Description: SWL works on the principle of focusing on the calculus using fluoroscopy. There has yet to be a consensus on the optimal frequency of fluoroscopic monitoring in the literature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave lithotripsy
Description: SWL works on the principle of focusing on the calculus using fluoroscopy. There has yet to be a consensus on the optimal frequency of fluoroscopic monitoring in the literature.
Study: NCT02752308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilute epinephrine injection
Description: Injection of 1/100000 epinephrine solution along all incision lines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dextrose plus sodium chloride.
Description: Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
Study: NCT06694909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS + PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study: NCT03018665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral，0.85g，twice a day in three months
Study: NCT06694909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS + sham PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + PNS without action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study: NCT02752308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dextrose plus sodium chloride.
Description: Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine and atropine
Description: Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine and atropine
Description: Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
Study: NCT04143607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ASK120067
Description: Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT02028039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 75 mg orally twice daily for 4 weeks.
Study: NCT02752308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypospadias repair
Description: Surgical repair of hypospadias, using tubularized incised plate technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypospadias repair
Description: Surgical repair of hypospadias, using tubularized incised plate technique
Study: NCT03002376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: REGN2810 treatment
Study: NCT02779387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Study: NCT02393651

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
Study: NCT02028039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up Visit/Call
Description: Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
Study: NCT01566435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
Study: NCT02940444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study: NCT03005366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vernakalant
Description: Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide
Description: 2 mg /kg (max 150 mg) intravenously over 10 minutes.
Study: NCT03098485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 5 days of levofloxacin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 5 days of azithromycin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 5 days of azithromycin administration
Study: NCT06694909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS + PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS + sham PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study: NCT03098485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefpodoxime
Description: 5 days of cefpodoxime administration
Study: NCT01157429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: 12-session CBT protocol, called Youth PTSD Treatment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: 12-session CBT protocol, called Youth PTSD Treatment.
Study: NCT03000127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel 1 % Topical Gel
Description: testosterone gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo gel
Study: NCT00095927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: Given subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT02393651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
Study: NCT04017975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescite
Description: 1 mL of Fluorescite will be diluted into 1L of saline. Up to 5mLs of the 1:1000 diluted solution will be applied topically to the cardiac tissue prior to imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio 100 Series System with Confocal Miniprobes
Description: The microscopy system will image cardiac tissue.
Study: NCT04081012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
Study: NCT00095927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study: NCT01402258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-administrated CBT-Treatment
Description: This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
Study: NCT04081012

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
Study: NCT00095927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03983655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Low Intensity TMS
Description: 125 hz, 10 gauss, 2 times daily for 6 monts

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Frequency Low Intensity TMS
Description: 125 hz, 10 gauss, 2 times daily for 6 monts
Study: NCT05019807

Intervention type: OTHER
Group type: OTHER
Intervention: WhatsApp group
Description: Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
Study: NCT01395537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Description: Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
Study: NCT04879381

Intervention type: OTHER
Intervention: Sputum samples
Description: During consultation, one expectoration will be performed.
Study: NCT00691782

Intervention type: OTHER
Intervention: Survey of exercise practices
Description: detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
Study: NCT04548258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric intraoral weilding
Description: weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: casting
Description: casting metal framework
Study: NCT03928405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises with Nintendo Wii virtual reality device
Description: In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
Study: NCT00095927

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: Given once daily for 4 weeks and then twice daily for 2 weeks.
Study: NCT00779519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP435

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01410019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene transfer
Description: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
Study: NCT00095927

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Given once daily for 4 weeks and then twice daily for 2 weeks.
Study: NCT01395537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
Study: NCT01580722

Intervention type: PROCEDURE
Group type: OTHER
Intervention: early reconstruction
Description: patients underwent \< 8 weeks reconstruction after injury

Intervention type: PROCEDURE
Group type: OTHER
Intervention: delay reconstruction
Description: patients underwent \> 8 weeks reconstruction after injury
Study: NCT03164356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance monitor
Description: Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
Study: NCT04423367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib/dexamethasone
Description: Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.
Study: NCT03665857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a multicomponent intervention
Description: 1. School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~2. Monitoring of students' weight and height Students will be monitored their weight and height monthly.~3. Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~4. Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~5. The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors.
Study: NCT03573102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT2 inhibitor 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Description: ACE inhibitor once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: ACE inhibitor once daily
Study: NCT04695587

Intervention type: DIAGNOSTIC_TEST
Intervention: 123 MIBG scintigraphy testing
Description: 123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.

Intervention type: DIAGNOSTIC_TEST
Intervention: MSNA
Description: MSNA in subacute phase and 12 months after the acute episode

Intervention type: DIAGNOSTIC_TEST
Intervention: ABPM
Description: ABPM in subacute phase and 12 months after the acute episode
Study: NCT00641147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04770818

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Brostrum procedure with Internal Brace Augmentation
Description: Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Brostrum procedure
Description: Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
Study: NCT01048203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-215050
Description: 1 mg ABR-215050
Study: NCT01373853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lens Fragmentation by means of a femtosecondlaser
Description: In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Phacoemulsification
Description: Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
Study: NCT00518505

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom questionnaire
Description: This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
Study: NCT03390361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser-assisted
Description: Laser cataract surgery will be performed in one eye

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Manual Cataract Surgery
Description: Manual cataract surgery will be performed in contralateral eye
Study: NCT02434952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin piperaquine (DHA PP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin piperaquine (DHA PP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin piperaquine (DHA PP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin piperaquine (DHA PP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Study: NCT02654379

Intervention type: BIOLOGICAL
Intervention: Rituximab
Description: Rituximab use in non-oncology indications
Study: NCT02320721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (HOE901 - U300)
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (HOE901 - U100)
Description: Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy
Description: Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
Study: NCT02514564

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
Study: NCT03929016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg
Study: NCT02398747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: 50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
Study: NCT00641147

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO